$SMMT

AstraZeneca (AZN) will invest $2 billion in Summit Therapeutics (SMMT) for a cancer drug partnership. The investment buys preferred shares convertible at $18.36, a premium to Summit's closing price. The companies will jointly trial Summit's ivonescimab with AstraZeneca's sonesitatug vedotin. AstraZeneca's investment is less than 1% of its market value, while Summit's shares are down year-over-year.

H.C. Wainwright reiterated a Neutral rating on Summit Therapeutics (NASDAQ: SMMT) after a $2 billion investment from AstraZeneca. The deal includes a 10% premium on the stock price and shared development costs for gastrointestinal cancer treatments. Summit's stock is trading at $16.39, down 36% in a week, with a market cap of $12.35 billion. Analysts have mixed ratings and price targets, ranging from $30 to $41.

Citizens reiterated a Market Outperform rating and $40.00 price target for Summit Therapeutics (NASDAQ:SMMT), citing a $2B AstraZeneca investment and clinical collaborations. The deal funds Summit's clinical and commercial efforts, with Phase 3 trial results expected in 2026-2027. Summit's proforma cash position is $2.8B, and its current ratio is 6.96. Multiple analysts maintain positive ratings and price targets.

Summit Therapeutics (SMMT) is seeking financing to meet operating cash needs, warning that failure could delay R&D and commercialization. Shares rose 20–27% premarket after a cancer therapy collaboration with AstraZeneca was announced.

Summit Therapeutics (SMMT) stock rose 6.23% after AstraZeneca invested $2B via convertible preferred stock, valuing SMMT at a 10% premium. The deal includes clinical collaboration on ivonescimab, with promising trial results. SMMT has no significant revenue, a net loss of $231.8M, and $238.6M in cash. Jefferies upgraded SMMT to Buy with a $25 price target.

Biotech stocks SLXN, SMMT, IOVA, NTHI rose on Sept 29, 2026, due to positive developments. SLXN surged 30% after preclinical data. SMMT gained 6% from AstraZeneca's $2.0B investment. IOVA rose 34% on raised revenue guidance. NTHI increased 7.59% ahead of FDA meeting.

Biotech stocks SLXN and SMMT rose premarket. SLXN gained on positive preclinical data, while SMMT jumped after a $2B equity investment from AZN. NIVF and QURE declined.

Stock futures mostly declined ahead of key inflation data. Navitas Semiconductor (NVTS) gained 14% after an Army grant. Sangoma Technologies (SCT) rose 39% on a $204M acquisition deal. Summit Therapeutics (SUM) climbed 17% following a $2B AstraZeneca investment. Oil prices fluctuated amid U.S.-Iran talks, and Treasury yields remained near multiyear highs.

Stifel reiterated a Buy rating and $38 price target for Summit Therapeutics (NASDAQ: SMMT), citing its $2.5B cash position to fund Phase 3 trials. The stock is down 10% in a week, with analysts' targets ranging from $10.76 to $40.78. Recent updates include a strong current ratio, strategic collaborations, and positive trial data. Other analysts also raised or maintained their price targets and ratings.

Jefferies raised its price target for Summit Therapeutics (NASDAQ:SMMT) to $30 from $25, maintaining a Buy rating. The move follows a strategic deal with a major oncology player, providing a cash infusion and validating the company's lead asset, ivonescimab. Analysts have varying price targets, ranging from $10.76 to $40.78, with recent positive trial data and strong financial health supporting optimistic outlooks.